trial

Accelerated TMS in Psychosis

NCTId NCT05567848
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Suspended
Enrollment 20 (estimated)
Sponsored by Beth Israel Deaconess Medical Center
Primary completion 2027-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Suspended
Enrollment
20 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2022-11-29
Primary completion
2027-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
repetitive Transcranial Magnetic Stimulation (rTMS)

Sponsors

Beth Israel Deaconess Medical CenterLead Sponsor

Investigators

1
Roscoe O Brady, MD, PhDPrincipal Investigator

Sites

1 total
Boston, United States

Linked catalysts

1
Accelerated TMS in Psychosis — primary completion2027-01

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE1,PHASE2
Primary Completion Date
2027-01
Status
SUSPENDED
relationships
The graph out of here
drug
repetitive Transcranial Magnetic Stimulation (rTMS)
drug
lead_sponsor
Beth Israel Deaconess Medical Center
company
indication
Prodromal Schizophrenia
indication
Schizotypal Personality Disorder
indication
Schizoaffective Disorder
indication
investigator
Roscoe O Brady, MD, PhD
person